Quantitative Mathematical Modeling of PSA Dynamics of Prostate Cancer Patients Treated with Intermittent Androgen Suppression

Overview

Journal J Mol Cell Biol

Publisher Oxford University Press

Specialty Molecular Biology

Date 2012 May 8

PMID 22561841

Citations 9

Authors

Yoshito Hirata

Koichiro Akakura

Celestia S Higano

Nicholas Bruchovsky

Kazuyuki Aihara

Affiliations

Soon will be listed here.

Abstract

If a mathematical model is to be used in the diagnosis, treatment, or prognosis of a disease, it must describe the inherent quantitative dynamics of the state. An ideal candidate disease is prostate cancer owing to the fact that it is characterized by an excellent biomarker, prostate-specific antigen (PSA), and also by a predictable response to treatment in the form of androgen suppression therapy. Despite a high initial response rate, the cancer will often relapse to a state of androgen independence which no longer responds to manipulations of the hormonal environment. In this paper, we present relevant background information and a quantitative mathematical model that potentially can be used in the optimal management of patients to cope with biochemical relapse as indicated by a rising PSA.

Citing Articles

Quantification and Optimization of Standard-of-Care Therapy to Delay the Emergence of Resistant Bone Metastatic Prostate Cancer.

Araujo A, Cook L, Frieling J, Tan W, Copland 2nd J, Kohli M Cancers (Basel). 2021; 13(4).

PMID: 33567529 PMC: 7915310. DOI: 10.3390/cancers13040677.

Modeling the Human Bone-Tumor Niche: Reducing and Replacing the Need for Animal Data.

Rao S, Edwards C, Edwards J JBMR Plus. 2020; 4(4):e10356.

PMID: 32258970 PMC: 7117847. DOI: 10.1002/jbm4.10356.

Massive computational acceleration by using neural networks to emulate mechanism-based biological models.

Wang S, Fan K, Luo N, Cao Y, Wu F, Zhang C Nat Commun. 2019; 10(1):4354.

PMID: 31554788 PMC: 6761138. DOI: 10.1038/s41467-019-12342-y.

PAGE4 and Conformational Switching: Insights from Molecular Dynamics Simulations and Implications for Prostate Cancer.

Lin X, Roy S, Jolly M, Bocci F, Schafer N, Tsai M J Mol Biol. 2018; 430(16):2422-2438.

PMID: 29758263 PMC: 6045464. DOI: 10.1016/j.jmb.2018.05.011.

Personalizing Androgen Suppression for Prostate Cancer Using Mathematical Modeling.

Hirata Y, Morino K, Akakura K, Higano C, Aihara K Sci Rep. 2018; 8(1):2673.

PMID: 29422657 PMC: 5805696. DOI: 10.1038/s41598-018-20788-1.

References

Bruchovsky N, Klotz L, Crook J, Phillips N, Abersbach J, Goldenberg S . Quality of life, morbidity, and mortality results of a prospective phase II study of intermittent androgen suppression for men with evidence of prostate-specific antigen relapse after radiation therapy for locally advanced prostate cancer. Clin Genitourin Cancer. 2008; 6(1):46-52. DOI: 10.3816/CGC.2008.n.008. View

Kuramae H, Hirata Y, Bruchovsky N, Aihara K, Suzuki H . Nonlinear systems identification by combining regression with bootstrap resampling. Chaos. 2012; 21(4):043121. DOI: 10.1063/1.3657919. View

Aihara K, Suzuki H . Theory of hybrid dynamical systems and its applications to biological and medical systems. Philos Trans A Math Phys Eng Sci. 2010; 368(1930):4893-914. DOI: 10.1098/rsta.2010.0237. View

Klein C . Parallel progression of primary tumours and metastases. Nat Rev Cancer. 2009; 9(4):302-12. DOI: 10.1038/nrc2627. View

Tanaka G, Hirata Y, Goldenberg S, Bruchovsky N, Aihara K . Mathematical modelling of prostate cancer growth and its application to hormone therapy. Philos Trans A Math Phys Eng Sci. 2010; 368(1930):5029-44. DOI: 10.1098/rsta.2010.0221. View

Chuu C, Hiipakka R, Fukuchi J, Kokontis J, Liao S . Androgen causes growth suppression and reversion of androgen-independent prostate cancer xenografts to an androgen-stimulated phenotype in athymic mice. Cancer Res. 2005; 65(6):2082-4. DOI: 10.1158/0008-5472.CAN-04-3992. View

Klotz L, Herr H, Morse M, WHITMORE Jr W . Intermittent endocrine therapy for advanced prostate cancer. Cancer. 1986; 58(11):2546-50. DOI: 10.1002/1097-0142(19861201)58:11<2546::aid-cncr2820581131>3.0.co;2-n. View

Kokontis J, Hsu S, Chuu C, Dang M, Fukuchi J, Hiipakka R . Role of androgen receptor in the progression of human prostate tumor cells to androgen independence and insensitivity. Prostate. 2005; 65(4):287-98. DOI: 10.1002/pros.20285. View

Hirata Y, di Bernardo M, Bruchovsky N, Aihara K . Hybrid optimal scheduling for intermittent androgen suppression of prostate cancer. Chaos. 2011; 20(4):045125. DOI: 10.1063/1.3526968. View

10.

Feldman B, Feldman D . The development of androgen-independent prostate cancer. Nat Rev Cancer. 2002; 1(1):34-45. DOI: 10.1038/35094009. View

11.

Attar R, Takimoto C, Gottardis M . Castration-resistant prostate cancer: locking up the molecular escape routes. Clin Cancer Res. 2009; 15(10):3251-5. DOI: 10.1158/1078-0432.CCR-08-1171. View

12.

Hu R, Dunn T, Wei S, Isharwal S, Veltri R, Humphreys E . Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Res. 2009; 69(1):16-22. PMC: 2614301. DOI: 10.1158/0008-5472.CAN-08-2764. View

13.

Hirata Y, Bruchovsky N, Aihara K . Development of a mathematical model that predicts the outcome of hormone therapy for prostate cancer. J Theor Biol. 2010; 264(2):517-27. DOI: 10.1016/j.jtbi.2010.02.027. View

14.

Bruchovsky N, Klotz L, Crook J, Goldenberg S . Locally advanced prostate cancer--biochemical results from a prospective phase II study of intermittent androgen suppression for men with evidence of prostate-specific antigen recurrence after radiotherapy. Cancer. 2007; 109(5):858-67. DOI: 10.1002/cncr.22464. View

15.

Eikenberry S, Nagy J, Kuang Y . The evolutionary impact of androgen levels on prostate cancer in a multi-scale mathematical model. Biol Direct. 2010; 5:24. PMC: 2885348. DOI: 10.1186/1745-6150-5-24. View

16.

Jain H, Clinton S, Bhinder A, Friedman A . Mathematical modeling of prostate cancer progression in response to androgen ablation therapy. Proc Natl Acad Sci U S A. 2011; 108(49):19701-6. PMC: 3241775. DOI: 10.1073/pnas.1115750108. View

17.

Kokontis J, Hay N, Liao S . Progression of LNCaP prostate tumor cells during androgen deprivation: hormone-independent growth, repression of proliferation by androgen, and role for p27Kip1 in androgen-induced cell cycle arrest. Mol Endocrinol. 1998; 12(7):941-53. DOI: 10.1210/mend.12.7.0136. View

18.

DiMonte G . A cell kinetics model for prostate cancer and its application to clinical data and individual patients. J Theor Biol. 2010; 264(2):420-42. DOI: 10.1016/j.jtbi.2010.02.023. View

19.

Yu E, Gulati R, Telesca D, Jiang P, Tam S, Russell K . Duration of first off-treatment interval is prognostic for time to castration resistance and death in men with biochemical relapse of prostate cancer treated on a prospective trial of intermittent androgen deprivation. J Clin Oncol. 2010; 28(16):2668-73. PMC: 2881848. DOI: 10.1200/JCO.2009.25.1330. View

20.

Higano C, Shields A, Wood N, Brown J, Tangen C . Bone mineral density in patients with prostate cancer without bone metastases treated with intermittent androgen suppression. Urology. 2004; 64(6):1182-6. DOI: 10.1016/j.urology.2004.07.019. View